Investigation of the Commercialization potential of an Oral Pharmaceutical to mitigate food Allergic reactions

Student: Kristen Stanis, 2018-2019

Sponsor: Allerief, Inc.

Millions of Americans suffer from food allergies. Unfortunately, for most people food allergic reactions range from mild to severe. Mild being merely bothersome symptoms, such as hives, swelling of the mouth, and tongue, gastrointestinal issues, like stomach cramping, pains, vomiting, and diarrhea. More severe reactions would mean life-threatening, anaphylactic shock. So, for those who do not qualify for an epinephrine auto-injector to reverse anaphylactic shock, they just suffer with the "mild" symptoms. Over the year, I will work in close conjunction with Allerief to develop an oral pharmaceutical that works to mitigate these "mild" symptoms associated with food allergic reactions. We will dive deep into identifying who the customer is, validating the problem, sizing the market, analyzing the competitive landscape, identifying key potential partners, and the production capabilities of pharmaceutical manufacturers.